Summary We developed an IgGI mouse monoclonal antibody (ONS-M21) directed against a cell surface antigen of medulloblastomas and gliomas in immunisation of mice with the ONS-76 medulloblastoma cell line. The antibody specifically reacted with medulloblastomas, supratentorial primitive neuroectodermal tumours (SPNETs) and gliomas, but not with other neuroectodermally derived tumours (neuroblastoma and melanoma) or with other kinds of tumours (meningioma, neurinoma, leukaemia, and small cell lung cancer). No reactivity was identified with normal body tissues, including peripheral blood cells. Characterisation of the ONS-M21 antigen showed that it was a trypsin-sensitive glycoprotein with a molecular weight of 80 kDa on SDS-PAGE. The pattern of reactivity and the biochemical properties of this antigen were different from those of other markers of medulloblastoma. These results indicate that ONS-M21 detects a new tumour-associated cell surface antigen specifically expressed by medulloblastomas, SPNETs, and gliomas. This is the first report that medulloblastomas may share common cell surface antigens with gliomas, although most studies have concluded that medulloblastoma has a predominantly neuronal phenotype. The lack of reactivity with normal tissue implies that ONS-M21 has potential applications as both a diagnostic tool and a therapeutic agent.
Medulloblastoma is the most common primitive neuroectodermal tumour (PNET) of the central nervous system in children (Rorke, 1983; Rorke et al., 1985; Dehner, 1986) . The survival rate of patients with medulloblastoma has increased over the past four decades due to multiple factors, including improvement of surgical techniques and postoperative care, but mainly due to advances in whole-neuroaxis radiotherapy (Farwell et al., 1984; Hershatter et al., 1986) . However, despite the recent advances in the treatment of many other childhood malignancies by combination chemotherapy, the long-term prognosis of medulloblastoma is still poor. The major reason for treatment failure is that recurrent tumours become insensitive to radiotherapy and chemotherapy (Pastan & Gottesman, 1987) . In this situation, a potential new therapeutic approach is the utilisation of monoclonal antibodies, as is done for autologous bone marrow transplantation with purged bone marrow (Coombes et al., 1986) .
So far, ten monoclonal antibodies (mAbs) directed against medulloblastomas have been described Allan et al., 1983; Jones et al., 1984; Gross et al., 1986; Wikstrand et al., 1986; Gibson & Kemshead, 1987; Feickert et al., 1989; Jennings et al., 1989; Takahashi et al., 1990) , but most of these antibodies also show reactivity with a broad range of other tumours and with normal tissues, making their in vivo use problematic.
In the present study, we tried to develop mAbs with an increased specificity for medulloblastoma. Assuming that any mAb will have some degree of cross-reactivity with normal tissues, we selected those which at least did not react with peripheral blood cells or normal brain tissue, thus increasing the possibility of their future clinical application.
Materials and methods

Cell lines
We used cultured human cell lines that were established from medulloblastomas and gliomas (Tamura et al., 1989; Okamoto et al., 1990; Moriuchi et al., 1991 (Tamura et al., 1989) . Three days after the last injection, two mice were sacrificed and their spleen cells were electrically fused with P3X63-Ag8,653 (JCRB 0028) myeloma cells (Zimmerman, 1982) . Then the supernatants of culture wells with growing clones were tested for specific antibodies by an enzyme-linked immunosorbent assay that assessed reactivity with cell surface antigens using a screening panel of cultured cell lines derived from medulloblastomas, gliomas, neuroblastomas, and other tumours. The selected clones were subcloned three times by limiting dilution and were injected intraperitoneally into BALB/c mice primed with 2,6,10,14-tetramethyl-pentadecane, after which mAbs were obtained from the ascitic fluid.
The immunoglobulin subclass of the cloned mAb (ONS-M21), was determined with a mouse mAb isotyping kit (Amersham, UK), and was shown to be IgGI. Its specificity was tested by flow cytometry using normal Characterisation of the ONS-M21 antigen ONS-76 cells were fixed with 70% ethanol for 30 min at 4°C. The cells were separately incubated overnight at 37°C with 0.1% trypsin (Nacalai Tesque, Inc., Kyoto, Japan), 0.1 U ml neuraminidase (Nacalai Tesque), or PBS, and then were incubated with ONS-M21 for 60 min at room temperature. Next, the cells were washed with PBS and incubated with FITC-labelled goat anti-mouse IgG.
Flow cytometry was performed using a FACScan cell sorter with excitation at 488 nm (15 mW). Gating was performed for both forward and right-angle scatter, and the resulting histograms (each containing data from 10,000 cells) were recorded on a three decade log scale. Evaluation of the data was done using a Hewlett-Packard 310-based computer system (CONSORT 30; Becton-Dickinson, San Jose, CA).
Immunohistochemical analysis
Frozen tissue sections (6,um) were fixed with cold acetone for 10 min, and then washed with PBS (pH 7.4) for 20 min. The sections were preincubated with 0.3% H202 in methanol for 20 min, washed three times with PBS, and then incubated with 5% normal goat serum in PBS for 30 min. Next the sections were incubated with 10 pg ml-' ONS-M21 for 2 h at room temperature (or overnight at 4°C), washed three times with PBS, and then incubated with biotinylated goat antimouse IgG (Dakopatts, Glostrup, Denmark) for 2 h at room temperature. After another wash with PBS, sections were incubated with streptavidin-biotin-peroxidase complex for 30 min at room temperature (Leong & Milios, 1987 , Ogawa et al., 1990 Raymond & Leong, 1990) . After a further wash with PBS, the peroxidase reaction was performed for 5 min using 0.06% diaminobenzidine with 0.01% H202 in 50 mM Tris-HCl buffer (pH 7.0). sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The dried gels were autoradiographed by exposure to X-ray film (Fuji X-ray film, RX). A glioblastoma cell line (T98G) and a neuroblastoma cell line (SK-N-DZ), which were respectively positive and negative for reaction with ONS-M21, were processed in the same manner as controls.
Affinity chromatography ONS-76 cells were grown to confluence in 100 cm2 dishes.
Approximately 1 x 109 cells were lysed with 0.5% Nonidet P-40 in Tris buffer as described previously (Wakabayashi et al., 1988) . Ascites containing ONS-M21 was purified with a protein A mAb purification kit (Bio-Rad Laboratories, Richmond, CA). The purified IgG thus obtained was used for subsequent conjugation to CNBr-activated sepharose, with 10 mg of IgG being coupled to I ml of sepharose. Nonidet P-40 extracts from ONS-76 cells were applied to the affinity column and extensively washed with PBS-phenylmethylsulphonylfluoride, after which the antigen was eluted using glycine hydrochloride buffer (pH 3.0) and was neutralised with 1.5 M Tris (pH 8.8). The material eluted from the column was subsequently analysed by SDS-PAGE. Because of the low protein concentration in the eluate, the gels were stained with silver.
Results
Expression of ONS-M21 antigen by cultured cell lines
The expression of ONS-M21 antigen by 46 established human tumour cell lines were tested using flow cytometry ( (Figure 4 ). This band was not detectable in a cell line that was negative for ONS-M21 staining (SK-N-DZ).
When the biochemical characteristics of the ONS-M21
antigen were examined by flow cytometry, it was shown to be Purification of ONS-M21 antigen from Nonidet P-40 extracts About 10 ml (4.6 mg ml-') of the Nonidet P-40 extract of ONS-76 cells was applied to a column of Sepherose 4B couples with ONS-M21. The column was washed extensively and then eluted with glycine hydrochloride buffer (pH 3.0). As shown in Figure 6 , purification with the immunoabsor- bent column was highly effective, and most of the protein in the Nonidet P-40 extracts emerged in the flow-through fraction without being adsorbed. Most of the antigenic activity was subsequently eluted by the glycine hydrochloride buffer, and when this purified material was analysed by SDS-PAGE, a single 80 kDa band was clearly visualised. 
Discussion
In the present study, the mAb ONS-M21 was raised against an established medullobastoma cell line (ONS-76). ONS-76 cells exhibit neuronal differentiation by expressing synaptophysin, neurofilament protein (200 and 145 kDa), and neuron-specific enolase (NSE), but retaina feature of gliomas by expressing human leukocyte antigen (HLA) DR in response to interferon-gamma (Tamura et al., 1989) . Most authors have concluded that medulloblastoma cell lines exhibit a predominantly neuronal phenotype (Trojanowski et al., 1987; He et al., 1989; He et al., 1991; Reed et al., 1991) . As far as we know, this study is the first report that medulloblastomas may express a neuroectodermal cell surface antigen shared with gliomas. Our initial screening suggested that this antibody did not react with normal human peripheral blood cells, or normal and foetal human cerebral tissues. Investigation of the reactivity of ONS-M21 with tumours revealed that its antigen was expressed by medulloblastomas, SPNETs, and gliomas. However, the antigen was not expressed by other neuroectodermally derived tumours, including neuroblastoma, melanoma, and chemodectoma. In addition, hematopoietic tumours such as leukaemia and other brain tumours like meningioma or neurinomas did not react with ONS-M21. Furthermore, small cell lung cancer lines which expressed NSE also showed no reactivity with ONS-M21 (Tanio et al., 1990; Tachibana et al., 1992) . Finally, normal human adult brain tissue and foetal brain tissue (23 or 32 weeks' gestation) showed no reactivity with ONS-M21, and neither did reactive astrocytes surrounding an arteriovenous malformation.
Biochemical studies showed that the ONS-M21 antigen was a membrane molecule on human medulloblastomas with a molecular weight of 80 kDa, and was a trypsin-sensitive, neuraminidase-resistant glycoprotein. Neuraminidase treatment mildly enhanced reactivity with ONS-M21, perhaps because the epitope became easier for the mAb to recognise without interference by sugar chains. The presence of this antigen in Nonidet P-40 extracts from medulloblastoma and glioma cell lines was confirmed.
In comparison with the previously described mAbs directed against medulloblastoma, ONS-M21 showed a different pattern of reactivity. The antigens defined by the mAbs CNT/2 and ASHE2 are expressed not only by medulloblastomas and gliomas, but also by normal brain tissue (Jones et al., 1984; Jennings et al., 1989) . In addition, the mAbs UJ127-11, 5A7, FMG25, and M148 are reactive with medulloblastomas and neuroblastomas, but not with gliomas Gross et al., 1986; Gibson et al., 1987; Takahashi et al., 1990) . Furthermore, the mAbs UJ13A and T-199 stain medulloblastomas, neuroblastomas, and gliomas, but they also react with normal brain tissue Feickert et al., 1989) . In contrast, the mAbs C12 and D12 react with the cytoplasm or cell membranes of gliomas and medulloblastomas, but not with neuroblastomas and normal brain tissue (Wikstrand et al., 1986) . The molecular weights of the antigens detected by C12 and D12 are 180 kDa and 88 kDa respectively.
The above findings suggest that the ONS-M21 antigen is a new tumour associated-antigen which is specifically expressed on the cell membranes of medulloblastomas, PNETs, and gliomas.
Bailey and Cushing described medulloblastomas as being derived from medulloblasts, the precursor cell of neuroblasts and glioblasts (Bailey & Cushing, 1925) . However, most atuhors have reported that medulloblastomas express only a neuronal phenotype. In contrast, the results of the present study indicate that medulloblastomas may share common neuroectodermal elements with gliomas, or else that medulloblastomas may have either a neuronal or a glial phenotype.
Since ONS-M21 reacts with medulloblastomas, PNETs, and gliomas, it may be useful in their differential diagnosis from other brain tumours. In addition, the strong reactivity of ONS-M21 with these brain tumours and its lack of reactivity with normal brain tissue may also allow its clinical application. Since ONS-M21 is an mAb of the IgGl subclass, its clinical application for conjugation to drugs, radionuclides, or toxins, is theoretically feasible.
